Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

ClinicalTrials.gov ID: NCT02669758

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02669758. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 10:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to evaluate the long term safety and tolerability of ALKS 3831 in subjects with schizophrenia.

Study identification

NCT ID
NCT02669758
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Alkermes, Inc.
Industry
Enrollment
281 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 20, 2016 (Actual)
Primary completion
Jun 29, 2018 (Actual)
Completion
Jun 29, 2018 (Actual)
Last update posted
Jul 26, 2019

2016 – 2018

United States locations

U.S. sites
14
U.S. states
9
U.S. cities
14
Facility City State ZIP Site status
Alkermes Investigational Site Little Rock Arkansas 72211 —
Alkermes Investigational Site Springdale Arkansas 72764 —
Alkermes Investigational Site Culver City California 90230 —
Alkermes Investigational Site Garden Grove California 92845 —
Alkermes Investigational Site Lemon Grove California 91945 —
Alkermes Investigational Site Orange California 92868 —
Alkermes Investigational Site San Diego California 92103 —
Alkermes Investigational Site Miami Florida 33161 —
Alkermes Investigational Site Chicago Illinois 60640 —
Alkermes Investigational Site St Louis Missouri 63141 —
Alkermes Investigational Site Las Vegas Nevada 89102 —
Alkermes Investigational Site Marlton New Jersey 08053 —
Alkermes Investigational Site Dayton Ohio 45417 —
Alkermes Investigational Site Dallas Texas 75243 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02669758, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 26, 2019 · Synced Nov 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.